(Q50557105)

15 March 2018

title

CYP2D6 genotype determination in the Danish population. (English)

1 reference

15 March 2018

author

Kim Brosen

1

1 reference

15 March 2018

Klaus Brusgaard

3

1 reference

15 March 2018

author name string

P N Nielsen

2

1 reference

15 March 2018

L F Gram

4

1 reference

15 March 2018

K Skjødt

5

1 reference

15 March 2018

publication date

1 January 1994

1 reference

15 March 2018

European Journal of Clinical Pharmacology

published in

1 reference

15 March 2018

volume

47

1 reference

15 March 2018

page(s)

221-225

1 reference

15 March 2018

issue

3

1 reference

15 March 2018

https://scigraph.springernature.com/pub.10.1007/bf02570501

exact match

0 references

cites work

Sparteine oxidation polymorphism: a family study

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02570501

Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene

21 January 2018

1 reference

12 December 2020

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

1 reference

12 December 2020

A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin

1 reference

12 December 2020

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

1 reference

12 December 2020

Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.

1 reference

12 December 2020

Sparteine metabolism in Canadian Caucasians

1 reference

12 December 2020

Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine.

1 reference

12 December 2020

Sparteine oxidation polymorphism in Denmark.

1 reference

12 December 2020

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

1 reference

12 December 2020

Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population

1 reference

12 December 2020

Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)

1 reference

12 December 2020

Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin

1 reference

12 December 2020

The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site

1 reference

12 December 2020

Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype

1 reference

12 December 2020

The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects

1 reference

12 December 2020

A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies

1 reference

12 December 2020

Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man

1 reference

12 December 2020

Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6.

1 reference

12 December 2020

Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine

1 reference

12 December 2020

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1 reference

12 December 2020

Genetic polymorphism of cytochromes P450: Interethnic differences and relationship to incidence of lung cancer

1 reference

12 December 2020

Genetically variable metabolism of antidepressants and neuroleptic drugs in man.

1 reference

12 December 2020

Debrisoquin oxidation genotype and susceptibility to lung cancer

1 reference

12 December 2020

The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature

1 reference

12 December 2020

Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs

1 reference

12 December 2020

The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene

1 reference

12 December 2020

Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease

1 reference

12 December 2020

Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?

1 reference

12 December 2020

Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes

1 reference

12 December 2020

The pharmacogenetics of the selective serotonin reuptake inhibitors

1 reference

12 December 2020

The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions

1 reference

12 December 2020

Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism

1 reference

12 December 2020

Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population

1 reference

12 December 2020

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

1 reference

12 December 2020

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02570501

1 reference

15 March 2018

PubMed ID

7867674

1 reference

15 March 2018